Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Innopharmax Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Innopharmax Inc. - Product Pipeline Review - 2014', provides an overview of the Innopharmax Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Innopharmax Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Innopharmax Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Innopharmax Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Innopharmax Inc.'s pipeline products Reasons to buy - Evaluate Innopharmax Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Innopharmax Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Innopharmax Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Innopharmax Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Innopharmax Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Innopharmax Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Innopharmax Inc. Snapshot 4 Innopharmax Inc. Overview 4 Key Information 4 Key Facts 4 Innopharmax Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Innopharmax Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Innopharmax Inc. - Pipeline Products Glance 12 Innopharmax Inc. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Innopharmax Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Phase 0 Products/Combination Treatment Modalities 14 Innopharmax Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Innopharmax Inc. - Drug Profiles 16 carvedilol CR 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 granisetron 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 gemcitabine hydrochloride 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 N-11005 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Innopharmax Inc. - Pipeline Analysis 21 Innopharmax Inc. - Pipeline Products by Target 21 Innopharmax Inc. - Pipeline Products by Route of Administration 23 Innopharmax Inc. - Pipeline Products by Molecule Type 24 Innopharmax Inc. - Pipeline Products by Mechanism of Action 25 Innopharmax Inc. - Recent Pipeline Updates 27 Innopharmax Inc. - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables Innopharmax Inc., Key Information 4 Innopharmax Inc., Key Facts 4 Innopharmax Inc. - Pipeline by Indication, 2014 7 Innopharmax Inc. - Pipeline by Stage of Development, 2014 8 Innopharmax Inc. - Monotherapy Products in Pipeline, 2014 9 Innopharmax Inc. - Partnered Products in Pipeline, 2014 10 Innopharmax Inc. - Partnered Products/ Combination Treatment Modalities, 2014 11 Innopharmax Inc. - Phase III, 2014 12 Innopharmax Inc. - Phase I, 2014 13 Innopharmax Inc. - Phase 0, 2014 14 Innopharmax Inc. - Preclinical, 2014 15 Innopharmax Inc. - Pipeline by Target, 2014 22 Innopharmax Inc. - Pipeline by Route of Administration, 2014 23 Innopharmax Inc. - Pipeline by Molecule Type, 2014 24 Innopharmax Inc. - Pipeline Products by Mechanism of Action, 2014 26 Innopharmax Inc. - Recent Pipeline Updates, 2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.